Voltar
Artigo Acesso aberto Produção Nacional Revisado por pares
BIBTEX RIS

Pulmonary Rehabilitation Associated with Noninvasive Ventilation on Physical Capacity and Quality of Life in Post-COVID-19: A Randomized Controlled Double-Blinded Clinical Trial Protocol

2024; Dove Medical Press; Volume: Volume 17; Linguagem: Inglês

10.2147/jmdh.s438120

ISSN

1178-2390

Autores

Guilherme Peixoto Tinoco Arêas, Cássia da Luz Goulart, Thaís Sant’Anna, Tiótrefis Gomes Fernandes, Rafael de Oliveira Alvim, Fernanda Borges, Camila Miriam Suemi Sato Barros do Amaral, Sebastião Cezar Rodrigues, Jefferson Valente, João Marcos Ferreira, A. C. Rezende, Edival Oliveira Júnior, Marcus Lacerda, Fernando Val,

Tópico(s)

Chronic Obstructive Pulmonary Disease (COPD) Research

Resumo

Background:The coronavirus disease-2019 (COVID-19) pulmonary rehabilitation (PR) seems to be a better choice to improve physical and functional capacity after acute infection.However, there is a lack of evidence regarding the effects of different strategies to optimize post-acute phase rehabilitation and reduce long COVID-19 physical deteriorations.Objective: To compare the use of a noninvasive ventilation (NIV) plus aerobic exercise strategy during PR program with to a standard PR (without NIV) on physical capacity and quality of life outcomes in post-COVID-19.Methods: Double-blinded randomized controlled clinical trial.A total of 100 individuals discharged from hospital in a post-acute phase of severe COVID-19 will be randomized into two groups: PR + NIV (Group 1) and PR (Group 2).Inclusion criteria include participants who present symptomatic dyspnea II and III by the modified Medical Research Council, aged 18 years or older.Both groups will receive aerobic and resistance exercise, and inspiratory muscle training.However, group 1 will perform aerobic training with bilevel NIV.Cardiopulmonary exercise test will assess the O 2 peak uptake, 6-minute walk test will assess the walking distance and short-form 36 will assess the quality of life before and after 8 weeks (after 24 PR sessions).Moreover, patients will be contacted by telephone every 3 months for one year to record possible adverse events, hospitalizations, and death.All data will be registered in RedCap, and analyses will be performed in the STATA v13 software.

Referência(s)